Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

roxadustat

AstraZeneca AZ

EU gives AZ’s Lynparza green light for BRCA-mutated pancreatic cancer

PARP inhibitor now available for rare, life-threatening disease

- PMLiVE

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

Antibody drug conjugate gained approval in US in December

AstraZeneca AZ

AZ’s Imfinzi gets US OK in small cell lung cancer, challenging Tecentriq

First checkpoint inhibitor to challenge Roche's Tecentriq in this indication

AstraZeneca AZ

AstraZeneca forms $2bn gene silencing pact with Silence Tx

Collaboration focuses on cardiovascular, renal, metabolic and respiratory disease

- PMLiVE

China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances

China secures a place at the forefront of innovative medicine

- PMLiVE

FDA green lights rapid coronavirus diagnostic test

Test can diagnose positive cases in approximately 45 minutes

- PMLiVE

FDA maintains COVID-19 therapeutics must meet a ‘gold standard’

Comes after President Trump called for expedited approval of potential treatments

- PMLiVE

Trump calls on FDA to cut ‘red tape’ as coronavirus drug trials gather pace

A number of candidates begin trial testing

- PMLiVE

Lilly partners with Indiana State Health Department for coronavirus testing

Experts maintain that testing can curb the outbreak

- PMLiVE

FDA knocks back DBV’s peanut allergy therapy once again

Drug loses further ground to Aimmune's Palforzia

AstraZeneca AZ

AZ’s Imfinzi plus tremelimumab combo misses again

Drug missed endpoint in small cell lung cancer trial

- PMLiVE

FDA green lights study of phage-based drug for resistant infections

Possible alternative to conventional antibiotics

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links